Biotech · Public company · Watertown, MA, US

C4 Therapeutics, Inc.

Ticker CCCC · SEC CIK 0001662579

Track this companyFree. Adds C4 Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials53 recruiting or active

Pipeline programs9From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline9

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaPHASE2 · RECRUITING · started Feb 18, 2026ClinicalTrials.gov NCT07284758 · fetched Nov 12, 2026
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma SubjectsPHASE1 · RECRUITING · started Feb 6, 2026ClinicalTrials.gov NCT07280013 · fetched Nov 12, 2026
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsPHASE1 · COMPLETED · started Dec 8, 2022ClinicalTrials.gov NCT05668585 · fetched Nov 12, 2026
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null TumorsPHASE1 · TERMINATED · started Mar 25, 2022ClinicalTrials.gov NCT05355753 · fetched Nov 12, 2026
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 27, 2021ClinicalTrials.gov NCT04756726 · fetched Nov 12, 2026